Ge Long Hui·2025-11-17 08:52Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Venlafaxine, which is primarily used for gastroesophageal reflux disease and is included in the 2025 National Basic Medical Insurance Drug List as a Class B drug [1] Company Summary - The company has announced the receipt of the approval notice for Fumaric Acid Venlafaxine, indicating a significant development in its product portfolio [1] - This approval may enhance the company's market position in the pharmaceutical industry, particularly in the treatment of gastroesophageal reflux disease [1] Industry Summary - The inclusion of Fumaric Acid Venlafaxine in the National Basic Medical Insurance Drug List suggests a growing recognition of the drug's importance in treating specific medical conditions [1] - The approval aligns with industry trends towards expanding access to essential medications through insurance coverage [1]